Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27436579 | 0.94 | POLRMT (0.42) | POLRMTBTN3A1CYP3A4CYP2C9 | |
| SCHEMBL23844104 | 0.94 | POLRMT (0.42) | POLRMTBTN3A1CYP3A4CYP2C9 | |
| SCHEMBL23844082 | 0.94 | CYP3A4 (0.42) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23843985 | 0.94 | CYP3A4 (0.42) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827933 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827937 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827960 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827958 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827966 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 | |
| SCHEMBL23827939 | 0.94 | POLRMT (0.43) | POLRMTBTN3A1CYP3A4CYP2C9RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4106876-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | POLRMT 76/4885BTN3A1 4438/4885CYP3A4 1416/4885 |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | POLRMT 76/4885BTN3A1 4438/4885CYP3A4 1416/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | POLRMT 76/4885BTN3A1 4438/4885CYP3A4 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.